Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview of IN8Bio, Inc.
IN8Bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of gamma-delta T cell-based immunotherapies for the treatment of solid and liquid tumors. Leveraging the unique properties of gamma-delta T cells, the company focuses on creating innovative therapies that address significant unmet medical needs in oncology. Gamma-delta T cells are a specialized subset of T cells with the innate ability to differentiate between healthy and diseased tissues, making them a promising tool for targeted cancer treatment.
Core Business and Technology
IN8Bio's proprietary DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop gamma-delta T cell therapies. These therapies are designed to enhance tumor targeting, improve treatment durability, and reduce the risk of toxicities often associated with other immunotherapies. Unlike traditional CAR-T therapies, gamma-delta T cells naturally secrete lower levels of inflammatory cytokines, potentially offering a safer and more tolerable treatment option.
Key Clinical Programs
- INB-400: A Phase 2 clinical program targeting newly diagnosed glioblastoma (GBM), a highly aggressive brain tumor with limited treatment options. INB-400 combines autologous gamma-delta T cells with the standard-of-care regimen to improve progression-free and overall survival rates.
- INB-100: A Phase 1 program focused on high-risk leukemia patients undergoing hematopoietic stem cell transplantation. This therapy utilizes haplo-matched allogeneic gamma-delta T cells to reduce relapse rates and improve long-term outcomes.
- Preclinical Pipeline: The company is also exploring additional product candidates, such as INB-200 and INB-300, targeting other solid and hematologic tumors.
Market Position and Differentiation
IN8Bio operates within the competitive landscape of cell-based immunotherapies, which includes CAR-T therapies and other T cell-based approaches. However, the company differentiates itself through its focus on gamma-delta T cells, which offer unique advantages such as innate tumor recognition and reduced risk of severe toxicities like cytokine release syndrome (CRS). This positions IN8Bio as a potential leader in the next generation of immunotherapies.
Challenges and Opportunities
As a clinical-stage company, IN8Bio faces challenges such as regulatory hurdles, manufacturing scalability, and the inherent risks of clinical development. However, its innovative approach and focus on addressing unmet medical needs provide significant opportunities for growth and impact within the biopharmaceutical industry.
Conclusion
IN8Bio, Inc. represents a cutting-edge approach to cancer treatment, utilizing the unique properties of gamma-delta T cells to develop therapies with the potential to transform outcomes for patients with difficult-to-treat cancers. Through its robust pipeline and proprietary technology, the company is well-positioned to make a meaningful impact in the field of oncology.
IN8bio, Inc. (Nasdaq: INAB) announced its participation in several upcoming virtual and hybrid conferences in March 2022. Key events include the European Society for Medical Oncology Congress on March 7-8, featuring a presentation on engineered γδ T-cells, and the Cowen 42nd Annual Health Care Conference on March 7, where CEO William Ho will discuss the company overview. Additional presentations will take place at the Oppenheimer Healthcare Conference and the European Society for Blood and Marrow Transplantation meeting.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company focused on gamma-delta T cell therapies, announced executive presentations at two upcoming events. The BIO CEO & Investor Conference will take place from February 14-17, 2022, featuring CEO Will Ho. Additionally, at the Next Generation CAR-TCR Summit in London on February 22-24, 2022, CSO Dr. Lawrence Lamb and COO Dr. Kate Rochlin will present relevant research on CAR-T cell therapies. IN8bio is advancing clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio (Nasdaq: INAB) announced that CEO William Ho will present at four virtual investor conferences in January 2022. Key events include:
- H.C. Wainwright & Co. BioConnect Conference: January 10-13
- Solebury Trout Management Access: January 10-13 & 18-20
- Biotech Showcase: January 10, 11:00 a.m. EST
- B. Riley Virtual Oncology Conference: January 27, 11:00 a.m. EST
IN8bio focuses on developing gamma-delta T cell therapies for cancers.
IN8bio, Inc. (Nasdaq: INAB) announced a promising update on INB-200, the first genetically modified gamma-delta T cell therapy in clinical trials for glioblastoma multiforme (GBM). Currently in a Phase 1 trial, Cohort 1 has completed dosing with no dose limiting toxicities or serious adverse events, while Cohort 2 is actively enrolling patients. Notably, all treated patients exceeded expected progression-free survival intervals, demonstrating a potential improvement in overall survival. The trial aims to assess safety, tolerability, and efficacy of the therapy combined with standard chemotherapy.
IN8bio has announced encouraging early results from its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for patients with acute myeloid leukemia (AML). Three patients have received treatment, all of whom remain in remission, with two achieving durable responses lasting over 1.5 years. The therapy demonstrated a manageable safety profile, with no significant adverse events reported. This trial aims to explore the efficacy of this novel treatment for patients undergoing haploidentical stem cell transplants, where relapse rates can be high.
IN8bio, Inc. (Nasdaq: INAB) has announced the promotion of Kate Rochlin, Ph.D., to Chief Operating Officer, effective immediately. Dr. Rochlin, who has been with IN8bio since August 2020, previously served as Vice President, Operations and Innovation. She will oversee multiple operational functions and will continue to lead early innovation programs. The company is advancing its gamma-delta T cell therapies aimed at treating solid and liquid tumors, utilizing its proprietary DeltEx platform. IN8bio is conducting two Phase 1 clinical trials for its lead product candidates.
IN8bio, Inc. has appointed Trishna Goswami, M.D. as Chief Medical Officer, effective immediately. Dr. Goswami brings over a decade of experience in immuno-oncology drug development, having worked with notable companies such as Gilead and AstraZeneca. Her expertise includes clinical development for both solid and hematologic tumors, making her a significant addition to IN8bio's leadership team. The company focuses on advancing gamma-delta T cell therapies using its DeltEx platform to improve cancer treatment outcomes. This appointment aligns with IN8bio's goal of progressing multiple therapeutic candidates through clinical development.
IN8bio (Nasdaq: INAB) announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 13, 2021. Dr. Kate Rochlin will present preclinical data on the potential of DeltEx drug-resistant immunotherapy gamma-delta T cells combined with PARP inhibitors to enhance tumor immunogenicity. Notably, temozolomide and niraparib resulted in up to a 29-fold increase in NKG2DL expression in resistant glioblastoma cell lines. This indicates the potential of orthogonal therapies to improve clinical efficacy against solid tumors.
IN8bio, Inc. (Nasdaq: INAB) raised $32.3 million in net proceeds from its IPO, enhancing its capital for clinical programs. The company completed patient dosing of INB-100 in a Phase 1 trial for leukemia while also publishing preclinical data on INB-200 in Scientific Reports. Financial results for Q3 2021 show a cash position of $40.7 million, with R&D expenses rising to $1.4 million. Net loss for the quarter was $3.4 million, compared to $1.7 million in Q3 2020. IN8bio continues to expect initial trial results in 2022 and topline results for all cohorts in 2023.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced its participation in three scientific conferences this November. Presentations will cover gammas-delta T-cell therapies aimed at treating various cancers. Key events include the Protein & Antibody Engineering Summit on November 4, the SITC Annual Meeting on November 13, and the Society for Neuro-Oncology meeting on November 19. Presenters include top executives and scientists from IN8bio, showcasing innovative cancer treatment approaches using the DeltEx platform.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is IN8Bio, Inc.'s primary focus?
What are gamma-delta T cells?
What are IN8Bio's key clinical programs?
How does IN8Bio differentiate itself from competitors?
What challenges does IN8Bio face?
What is the DeltEx platform?
What types of cancers does IN8Bio target?
What is INB-400?
What is the significance of INB-100?
What makes gamma-delta T cell therapies safer than CAR-T therapies?
